Matinas Biopharma (MTNB)
(Real Time Quote from BATS)
$3.61 USD
-0.07 (-1.90%)
Updated Sep 24, 2024 02:58 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Matinas Biopharma Holdings, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 1 | 3 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 1 | 3 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 25 | 28 | 25 | 24 | 19 |
Income After Depreciation & Amortization | -24 | -25 | -25 | -24 | -19 |
Non-Operating Income | 1 | 4 | 1 | 2 | 2 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -23 | -21 | -23 | -22 | -17 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -23 | -21 | -23 | -22 | -17 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -23 | -21 | -23 | -22 | -17 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -23 | -23 | -24 | -23 | -18 |
Depreciation & Amortization (Cash Flow) | 1 | 1 | 1 | 1 | 1 |
Income After Depreciation & Amortization | -24 | -25 | -25 | -24 | -19 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 4.35 | 4.34 | 4.20 | 3.94 | 2.90 |
Diluted EPS Before Non-Recurring Items | -5.50 | -5.00 | -5.50 | -6.00 | -6.50 |
Diluted Net EPS (GAAP) | -5.50 | -5.00 | -5.50 | -6.00 | -6.50 |
Fiscal Year end for Matinas Biopharma Holdings, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 5.84 | 5.91 | 5.89 | 6.14 | 6.16 |
Income After SG&A, R&D, and Dept/Amort Expenses | -5.84 | -5.91 | -5.89 | -6.14 | -6.16 |
Non-Operating Income | 0.12 | 0.08 | 0.09 | 0.08 | 0.10 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -5.72 | -5.82 | -5.31 | -6.06 | -6.06 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -5.72 | -5.82 | -5.31 | -6.06 | -6.06 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -5.72 | -5.82 | -5.31 | -6.06 | -6.06 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 4.99 | 4.35 | 4.35 | 4.35 | 4.35 |
Diluted EPS Before Non-Recurring Items | -1.00 | -1.50 | -1.50 | -1.50 | -1.50 |
Diluted Net EPS (GAAP) | -1.00 | -1.50 | -1.00 | -1.50 | -1.50 |